Literature DB >> 28084005

Oral mucous membrane pemphigoid and pemphigus vulgaris-a retrospective two-center cohort study.

A S Sultan1,2, A Villa1,2, A P Saavedra3, N S Treister1,2, S-B Woo1,2.   

Abstract

OBJECTIVES: Few studies have compared oral mucous membrane pemphigoid (MMP) and pemphigus vulgaris (PV). Descriptive analysis of oral features, extent of extra-oral involvement, and management outcomes were performed. SUBJECTS AND METHODS: Patients with PV and MMP, the latter with exclusive oral involvement at first presentation, were included.
RESULTS: There were 26 MMP (46%) and 31 PV (54%) patients. Desquamative gingivitis was evident in 84% of MMP cases compared to 28% of PV cases (P < 0.05). Non-gingival lesions were noted in 6% of MMP cases compared to 55% of PV cases (P < 0.01). Management of MMP consisted of only topical corticosteroids in 88% of cases while 12% of cases required concomitant systemic therapy. All PV cases (100%) required systemic therapy. No patients with MMP developed scarring or ocular lesions, and one patient (4%) developed cutaneous lesions. Five PV cases (16%) had oral cavity involvement only with three (60%) developing pharyngeal involvement and two (40%) developing cutaneous lesions on follow-up.
CONCLUSION: Oral MMP presents primarily as desquamative gingivitis, infrequently involving extragingival sites, and is highly amenable to topical therapy, while PV is a systemic mucocutaneous disease with extensive non-gingival oral lesions that almost always requires systemic therapy.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  desquamative gingivitis; gingival involvement; oral manifestations; oral mucous membrane pemphigoid; oral pemphigus vulgaris

Mesh:

Substances:

Year:  2017        PMID: 28084005     DOI: 10.1111/odi.12639

Source DB:  PubMed          Journal:  Oral Dis        ISSN: 1354-523X            Impact factor:   3.511


  7 in total

1.  Oral mucous membrane pemphigoid in a group of Thai patients-A 15-year retrospective study.

Authors:  Waranun Buajeeb; Kununya Pimolbutr; Naruemon Panpradit; Nis Okuma
Journal:  J Dent Sci       Date:  2021-11-24       Impact factor: 3.719

Review 2.  Oral Lesions in Autoimmune Bullous Diseases: An Overview of Clinical Characteristics and Diagnostic Algorithm.

Authors:  Hanan Rashid; Aniek Lamberts; Gilles F H Diercks; Hendri H Pas; Joost M Meijer; Maria C Bolling; Barbara Horváth
Journal:  Am J Clin Dermatol       Date:  2019-12       Impact factor: 7.403

Review 3.  Immunoglobulin Disorders and the Oral Cavity: A Narrative Review.

Authors:  Maja Ptasiewicz; Dominika Bębnowska; Paulina Małkowska; Olga Sierawska; Agata Poniewierska-Baran; Rafał Hrynkiewicz; Paulina Niedźwiedzka-Rystwej; Ewelina Grywalska; Renata Chałas
Journal:  J Clin Med       Date:  2022-08-19       Impact factor: 4.964

Review 4.  Immune checkpoint inhibitors in cancer therapy: Review of orofacial adverse events and role of the oral healthcare provider.

Authors:  Brittany A Klein; Muhammad Ali Shazib; Alessandro Villa; Fábio de Abreu Alves; Piamkamon Vacharotayangul; Stephen Sonis; Stefano Fedele; Nathaniel S Treister
Journal:  Front Oral Health       Date:  2022-08-11

Review 5.  Burden of pemphigus vulgaris with a particular focus on women: A review.

Authors:  Nika Kianfar; Shayan Dasdar; Hamidreza Mahmoudi; Maryam Daneshpazhooh
Journal:  Int J Womens Dermatol       Date:  2022-10-03

6.  Oral Pemphigus Vulgaris Treatment with Corticosteroids and Azathioprine: A Long-Term Study in Shiraz, Iran.

Authors:  Mehdy Davarmanesh; Maryam Zahed; Asma Sookhakian; Sina Jehbez
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-17       Impact factor: 2.650

7.  European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part I.

Authors:  H Rashid; A Lamberts; L Borradori; S Alberti-Violetti; R J Barry; M Caproni; B Carey; M Carrozzo; F Caux; G Cianchini; A Corrà; G F H Diercks; F G Dikkers; G Di Zenzo; C Feliciani; G Geerling; G Genovese; M Hertl; P Joly; A V Marzano; J M Meijer; V Mercadante; D F Murrell; M Ormond; H H Pas; A Patsatsi; C Prost; S Rauz; B D van Rhijn; M Roth; E Schmidt; J Setterfield; G Zambruno; D Zillikens; B Horváth
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-07-10       Impact factor: 6.166

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.